{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:48:28Z","timestamp":1777589308288,"version":"3.51.4"},"reference-count":115,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Biology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.repbio.2014.01.002","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T01:46:23Z","timestamp":1390355183000},"page":"16-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Tumor models for prostate cancer exemplified by fibroblast growth factor 8-induced tumorigenesis and tumor progression"],"prefix":"10.1016","volume":"14","author":[{"given":"Johanna","family":"Tuomela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pirkko","family":"H\u00e4rk\u00f6nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repbio.2014.01.002_bib0005","first-page":"27","article-title":"Anatomy of the prostate and morphogenesis of BPH","volume":"145","author":"McNeal","year":"1984","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0090-4295(99)00205-8","article-title":"Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network","volume":"54","author":"Nickel","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.repbio.2014.01.002_bib0015","first-page":"389","article-title":"Atypical adenomatous hyperplasia of the prostate: a premalignant lesion?","volume":"58","author":"Cheng","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","article-title":"Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging","volume":"111","author":"Gleason","year":"1974","journal-title":"J Urol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0025","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(08)60729-1","article-title":"Prostate cancer","volume":"371","author":"Damber","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.repbio.2014.01.002_bib0030","first-page":"439","article-title":"High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20\u201369: an autopsy study of 249 cases","volume":"8","author":"Sakr","year":"1994","journal-title":"In Vivo"},{"key":"10.1016\/j.repbio.2014.01.002_bib0035","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1001\/jama.291.22.2713","article-title":"Natural history of early, localized prostate cancer","volume":"291","author":"Johansson","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.repbio.2014.01.002_bib0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, 1941","volume":"168","author":"Huggins","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0094-0143(05)70066-5","article-title":"The biology of hormone refractory prostate cancer. Why does it develop?","volume":"26","author":"Isaacs","year":"1999","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.repbio.2014.01.002_bib0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ctrv.2012.09.005","article-title":"Progress in emerging therapies for advanced prostate cancer","volume":"39","author":"Oudard","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.repbio.2014.01.002_bib0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14712598.2013.840582","article-title":"Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer","volume":"14","author":"Dellis","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.repbio.2014.01.002_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S25537","article-title":"Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease","volume":"5","author":"Harrison","year":"2013","journal-title":"Cancer Manage Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0065","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S1470-2045(07)70284-X","article-title":"Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data","volume":"8","author":"Fizazi","year":"2007","journal-title":"Lancet Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.repbio.2014.01.002_bib0070","first-page":"S48","article-title":"The treatment of hormone-refractory prostate cancer: docetaxel and beyond","volume":"8","author":"Petrylak","year":"2006","journal-title":"Rev Urol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0075","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","article-title":"Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0080","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.coph.2008.06.004","article-title":"Targeting CYP17: established and novel approaches in prostate cancer","volume":"8","author":"Yap","year":"2008","journal-title":"Curr Opin Pharmacol"},{"issue":"21","key":"10.1016\/j.repbio.2014.01.002_bib0085","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-13-1550","article-title":"Targeting fibroblast growth factor pathways in prostate cancer","volume":"19","author":"Corn","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0090","doi-asserted-by":"crossref","first-page":"13958","DOI":"10.3390\/ijms140713958","article-title":"Recent progress in pharmaceutical therapies for castration-resistant prostate cancer","volume":"14","author":"Yin","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.repbio.2014.01.002_bib0095","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.2007.15.1472","article-title":"Prostate cancer stem cells: a new target for therapy","volume":"26","author":"Maitland","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0100","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/jcp.21489","article-title":"Stem cells: the root of prostate cancer?","volume":"216","author":"Kasper","year":"2008","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0105","doi-asserted-by":"crossref","first-page":"767","DOI":"10.5114\/aoms.2012.31610","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis","volume":"8","author":"Kawalec","year":"2012","journal-title":"Arch Med Sci"},{"issue":"Suppl. 3","key":"10.1016\/j.repbio.2014.01.002_bib0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000088479","article-title":"VEGF as a therapeutic target in cancer","volume":"69","author":"Ferrara","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.repbio.2014.01.002_bib0125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.repbio.2014.01.002_bib0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cytogfr.2005.01.004","article-title":"Fibroblast growth factor\/fibroblast growth factor receptor system in angiogenesis","volume":"16","author":"Presta","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.repbio.2014.01.002_bib0135","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1677\/erc.1.01290","article-title":"Role of hypoxia-inducible factor-1alpha as a cancer therapy target","volume":"13","author":"Patiar","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0145","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/0008-5472.CAN-04-2427","article-title":"Endogenous inhibitors of angiogenesis","volume":"65","author":"Nyberg","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0150","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repbio.2014.01.002_bib0155","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.bcp.2009.01.006","article-title":"Acute and chronic in vivo therapeutic resistance","volume":"77","author":"Teicher","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0160","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/1097-0045(20000601)43:4<286::AID-PROS8>3.0.CO;2-0","article-title":"Prostatic intraepithelial neoplasia: animal models 2000","volume":"43","author":"Bostwick","year":"2000","journal-title":"Prostate"},{"key":"10.1016\/j.repbio.2014.01.002_bib0165","first-page":"1303","article-title":"Factors in prostate cancer metastasis","volume":"10","author":"Geldof","year":"1990","journal-title":"Anticancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0045(19980915)37:1<1::AID-PROS1>3.0.CO;2-L","article-title":"Lobund-Wistar rat model of prostate cancer in man","volume":"37","author":"Pollard","year":"1998","journal-title":"Prostate"},{"key":"10.1016\/j.repbio.2014.01.002_bib0175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1159\/000019879","article-title":"Use of animal models in defining efficacy of chemoprevention agents against prostate cancer","volume":"35","author":"Bosland","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0180","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1095\/biolreprod34.5.961","article-title":"Morphogenesis of ductal networks in the mouse prostate","volume":"34","author":"Sugimura","year":"1986","journal-title":"Biol Reprod"},{"key":"10.1016\/j.repbio.2014.01.002_bib0185","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1677\/erc.0.0110225","article-title":"Genetically defined mouse models that mimic natural aspects of human prostate cancer development","volume":"11","author":"Roy-Burman","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0190","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/ijc.2910240605","article-title":"Metastasis of human tumors in athymic nude mice","volume":"24","author":"Sharkey","year":"1979","journal-title":"Int J Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/pros.2990150212","article-title":"Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice","volume":"15","author":"Shevrin","year":"1989","journal-title":"Prostate"},{"key":"10.1016\/j.repbio.2014.01.002_bib0200","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z","article-title":"Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID\/bg mice using LNCaP and lineage-derived metastatic sublines","volume":"77","author":"Wu","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0205","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pros.10091","article-title":"Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells","volume":"52","author":"Corey","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.repbio.2014.01.002_bib0210","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/pros.20913","article-title":"Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss","volume":"69","author":"Wakchoure","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.repbio.2014.01.002_bib0215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ijc.23422","article-title":"FGF-8 is involved in bone metastasis of prostate cancer","volume":"123","author":"Valta","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0220","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/jnci\/84.12.951","article-title":"Metastatic model for human prostate cancer using orthotopic implantation in nude mice","volume":"84","author":"Stephenson","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.repbio.2014.01.002_bib0225","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/pros.2990260502","article-title":"Spontaneous metastasis of PC-3 cells in athymic mice after implantation in orthotopic or ectopic microenvironments","volume":"26","author":"Waters","year":"1995","journal-title":"Prostate"},{"key":"10.1016\/j.repbio.2014.01.002_bib0230","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2407-8-81","article-title":"Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice","volume":"8","author":"Tuomela","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/pros.10290","article-title":"Molecular characterization of human prostate carcinoma cell lines","volume":"57","author":"van Bokhoven","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.repbio.2014.01.002_bib0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bjc.6604822","article-title":"Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer","volume":"100","author":"van Weerden","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0245","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/bi00123a026","article-title":"Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation","volume":"31","author":"Veldscholte","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.repbio.2014.01.002_bib0250","first-page":"163","article-title":"VCaP, a cell-based model system of human prostate cancer","volume":"15","author":"Korenchuk","year":"2001","journal-title":"In Vivo"},{"key":"10.1016\/j.repbio.2014.01.002_bib0255","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11626-999-0115-4","article-title":"A new human prostate carcinoma cell line, 22Rv1","volume":"35","author":"Sramkoski","year":"1999","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"10.1016\/j.repbio.2014.01.002_bib0260","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jsbmb.2012.01.005","article-title":"Breaking through a roadblock in prostate cancer research: an update on human model systems","volume":"131","author":"Toivanen","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0265","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1126\/science.1189992","article-title":"Identification of a cell of origin for human prostate cancer","volume":"329","author":"Goldstein","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.repbio.2014.01.002_bib0270","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1158\/1078-0432.CCR-06-0482","article-title":"Mouse modeling in oncologic preclinical and translational research","volume":"12","author":"Carver","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0275","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0092-8674(02)00621-9","article-title":"Cancer modeling in the modern era: progress and challenges","volume":"108","author":"Van Dyke","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.repbio.2014.01.002_bib0280","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1126\/science.1957168","article-title":"Transgenic models of tumor development","volume":"254","author":"Adams","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.repbio.2014.01.002_bib0285","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1097-0045(19980615)36:1<59::AID-PROS11>3.0.CO;2-H","article-title":"Workgroup 3: transgenic and reconstitution models of prostate cancer","volume":"36","author":"Green","year":"1998","journal-title":"Prostate"},{"key":"10.1016\/j.repbio.2014.01.002_bib0290","first-page":"309","article-title":"Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models","volume":"394","author":"Bosland","year":"1996","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0295","first-page":"4096","article-title":"Metastatic prostate cancer in a transgenic mouse","volume":"56","author":"Gingrich","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0300","first-page":"i","article-title":"Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer","volume":"78","author":"Kasper","year":"1998","journal-title":"Lab Invest"},{"key":"10.1016\/j.repbio.2014.01.002_bib0305","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1073\/pnas.92.8.3439","article-title":"Prostate cancer in a transgenic mouse","volume":"92","author":"Greenberg","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.repbio.2014.01.002_bib0310","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2353\/ajpath.2008.070602","article-title":"Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer","volume":"172","author":"Chiaverotti","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0315","first-page":"4693","article-title":"Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent","volume":"61","author":"Asamoto","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0320","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2407-9-30","article-title":"Characterization of SV-40 Tag rats as a model to study prostate cancer","volume":"9","author":"Harper","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0325","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng0497-356","article-title":"Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers","volume":"15","author":"Steck","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.repbio.2014.01.002_bib0330","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","article-title":"Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer","volume":"4","author":"Wang","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.repbio.2014.01.002_bib0335","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/excr.2000.5130","article-title":"PTEN: life as a tumor suppressor","volume":"264","author":"Simpson","year":"2001","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0340","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1371\/journal.pbio.0000059","article-title":"Pten dose dictates cancer progression in the prostate","volume":"1","author":"Trotman","year":"2003","journal-title":"PLoS Biol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0345","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1535-6108(03)00197-1","article-title":"Myc-driven murine prostate cancer shares molecular features with human prostate tumors","volume":"4","author":"Ellwood-Yen","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.repbio.2014.01.002_bib0350","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/geno.1997.4715","article-title":"A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer","volume":"43","author":"He","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.repbio.2014.01.002_bib0355","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0092-8674(91)90382-9","article-title":"Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging","volume":"65","author":"van Lohuizen","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.repbio.2014.01.002_bib0360","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10585-006-9002-5","article-title":"Rat models of bone metastases","volume":"22","author":"Blouin","year":"2005","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.repbio.2014.01.002_bib0365","first-page":"517","article-title":"Histogenesis and morphology of naturally occurring prostatic carcinoma in the ACI\/segHapBR rat","volume":"43","author":"Ward","year":"1980","journal-title":"Lab Invest"},{"key":"10.1016\/j.repbio.2014.01.002_bib0370","first-page":"1929","article-title":"The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration","volume":"37","author":"Noble","year":"1977","journal-title":"Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0375","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/pros.20719","article-title":"Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat","volume":"68","author":"Bernoulli","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.repbio.2014.01.002_bib0380","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2605.2008.00930.x","article-title":"Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio","volume":"32","author":"Yatkin","year":"2009","journal-title":"Int J Androl"},{"key":"10.1016\/j.repbio.2014.01.002_bib0385","first-page":"3282","article-title":"Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats","volume":"58","author":"McCormick","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0390","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1383-5742(00)00039-9","article-title":"Experimental prostate carcinogenesis \u2013 rodent models","volume":"462","author":"Shirai","year":"2000","journal-title":"Mutat Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0395","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1186\/gb-2001-2-3-reviews3005","article-title":"Fibroblast growth factors","volume":"2","author":"Ornitz","year":"2001","journal-title":"Genome Biol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0400","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.repbio.2014.01.002_bib0405","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1038\/sj.onc.1202624","article-title":"FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease","volume":"18","author":"Dorkin","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.repbio.2014.01.002_bib0410","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/labinvest.3780291","article-title":"Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer","volume":"81","author":"Valve","year":"2001","journal-title":"Lab Invest"},{"key":"10.1016\/j.repbio.2014.01.002_bib0415","first-page":"2053","article-title":"High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8","volume":"58","author":"Tanaka","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0420","first-page":"1425","article-title":"Molecular cloning and characterization of human FGF8 alternative messenger RNA forms","volume":"7","author":"Ghosh","year":"1996","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.repbio.2014.01.002_bib0425","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/sj.bjc.6600875","article-title":"FGF8 isoform b expression in human prostate cancer","volume":"88","author":"Gnanapragasam","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0430","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/sj.onc.1201652","article-title":"Downregulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems","volume":"16","author":"Rudra-Ganguly","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.repbio.2014.01.002_bib0435","first-page":"6730","article-title":"The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells","volume":"60","author":"Song","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0440","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/en.2005-1502","article-title":"Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8","volume":"147","author":"Valta","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.repbio.2014.01.002_bib0445","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/sj.onc.1204430","article-title":"FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells","volume":"20","author":"Mattila","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.repbio.2014.01.002_bib0450","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1593\/neo.10776","article-title":"Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice","volume":"12","author":"Elo","year":"2010","journal-title":"Neoplasia"},{"issue":"157","key":"10.1016\/j.repbio.2014.01.002_bib0455","first-page":"1","article-title":"Fibroblast growth factor 8b causes progressive stromal and epithelial changes in the epididymis and degeneration of the seminiferous epithelium in the testis of transgenic mice","volume":"86","author":"Elo","year":"2012","journal-title":"Biol Reprod"},{"key":"10.1016\/j.repbio.2014.01.002_bib0460","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mce.2006.04.007","article-title":"Androgen and fibroblast growth factor 8 (FGF8) downregulation of thrombospondin 1 (TSP1) in mouse breast cancer cells","volume":"253","author":"Mattila","year":"2006","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0465","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1054\/bjoc.2001.1971","article-title":"Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer","volume":"85","author":"West","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0470","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/jcb.22175","article-title":"FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer","volume":"107","author":"Valta","year":"2009","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.repbio.2014.01.002_bib0475","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/1471-2407-10-596","article-title":"Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts","volume":"10","author":"Tuomela","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0480","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrc1367","article-title":"Exploiting tumour hypoxia in cancer treatment","volume":"4","author":"Brown","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0485","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1073\/pnas.98.2.398","article-title":"Can mosaic tumor vessels facilitate molecular diagnosis of cancer?","volume":"98","author":"Folkman","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.repbio.2014.01.002_bib0490","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/sj.bjc.6600610","article-title":"Induction of vasculogenesis in breast cancer models","volume":"87","author":"Shirakawa","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0495","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.2174\/138161208786404380","article-title":"Imaging of tumor hypoxia to predict treatment sensitivity","volume":"14","author":"Minn","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.repbio.2014.01.002_bib0500","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/j.1460-2075.1996.tb00521.x","article-title":"A novel vascular endothelial growth factor VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases","volume":"15","author":"Joukov","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.repbio.2014.01.002_bib0505","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1073\/pnas.93.5.1988","article-title":"Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4","volume":"93","author":"Lee","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.repbio.2014.01.002_bib0510","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.molonc.2013.02.007","article-title":"Mouse models for studying angiogenesis and lymphangiogenesis in cancer","volume":"7","author":"Eklund","year":"2013","journal-title":"Mol Oncol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0515","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/1471-2407-9-362","article-title":"Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors","volume":"9","author":"Tuomela","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0520","doi-asserted-by":"crossref","first-page":"8868","DOI":"10.1073\/pnas.062040199","article-title":"Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea","volume":"99","author":"Kubo","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.repbio.2014.01.002_bib0525","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nm848","article-title":"Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2","volume":"9","author":"Cao","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.repbio.2014.01.002_bib0530","article-title":"FGF receptors: cancer biology and therapeutics","author":"Katoh","year":"2013","journal-title":"Med Res Rev"},{"key":"10.1016\/j.repbio.2014.01.002_bib0535","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1677\/erc.1.00535","article-title":"The role of fibroblast growth factors and their receptors in prostate cancer","volume":"11","author":"Kwabi-Addo","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0540","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/path.2205","article-title":"Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer","volume":"213","author":"Sahadevan","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.repbio.2014.01.002_bib0545","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccr.2007.11.004","article-title":"Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition","volume":"12","author":"Acevedo","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.repbio.2014.01.002_bib0550","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/0008-5472.CAN-12-3274","article-title":"FGFR1 is essential for prostate cancer progression and metastasis","volume":"73","author":"Yang","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0555","doi-asserted-by":"crossref","first-page":"e49970","DOI":"10.1371\/journal.pone.0049970","article-title":"Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth","volume":"7","author":"Tarkkonen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.repbio.2014.01.002_bib0560","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1158\/1078-0432.CCR-11-3214","article-title":"Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression","volume":"18","author":"Feng","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0565","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/bjc.2011.440","article-title":"Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients","volume":"105","author":"Bousquet","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.repbio.2014.01.002_bib0570","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10637-012-9851-5","article-title":"The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258","volume":"31","author":"Vallo","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.repbio.2014.01.002_bib0575","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.repbio.2014.01.002_bib0580","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2012.07.001","article-title":"Anticancer molecules targeting fibroblast growth factor receptors","volume":"33","author":"Liang","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.repbio.2014.01.002_bib0585","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.4181","article-title":"Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer","volume":"230","author":"Ronca","year":"2013","journal-title":"J Pathol"}],"container-title":["Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1642431X14000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1642431X14000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T21:58:11Z","timestamp":1565128691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1642431X14000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1642431X14000035"],"URL":"https:\/\/doi.org\/10.1016\/j.repbio.2014.01.002","relation":{},"ISSN":["1642-431X"],"issn-type":[{"value":"1642-431X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor models for prostate cancer exemplified by fibroblast growth factor 8-induced tumorigenesis and tumor progression","name":"articletitle","label":"Article Title"},{"value":"Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repbio.2014.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Society for Biology of Reproduction & the Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}